Saarland University Medical Center and Saarland University Faculty of Medicine
Klinik für Strahlentherapie und Radioonkologie
Leitung: Univ. Prof. Dr. med. M. Hecht
Sie befinden sich hier: >> Startseite >> Klinische Zentren und Einrichtungen >> Departments and Institutes >> Radiologie >> Strahlentherapie >> Forschung >> Publikationen

Publikationen seit 2012

 

2020

 

Jagoda P., Dzierma Y., Ziegenhain F., Speicher K., Rübe Ch., Buecker A., Minko P.:Establishment of Submillisievert Abdominal CT Protocols With an In Vivo Swine Model and an Anthropomorphic Phantom. American Journal of Roentgenology (2020); 215:685-694; DOI 10.2214/AJR.19.22053 PMID: 32755203

 

Applegate K.E., Rühm W., Wojcik A., Bourguignon M., Brenner A., Hamasaki K., Imai T., Imaizumi M., Imaoka T., Kakinuma S., Kamada T., Nishimura N., Okonogi N., Ozasa K., Rübe C.E., Sadakane A., Sakata R., Shimada Y., Yoshida K., Bouffler S.: Individual response of humans to ionising radiation: governing factors and importance for radiological protection. RADIAT ENVIRON BIOPH (2020); 59:185-209; DOI: 10.1007/s00411-020-00837-yPMID: 32146555

Fajardo R.D., van den Heuvel-Eibrink M.M., van Tinteren H., Spreafico F., Acha T., Bergeron C., de Camargo B., Oldenburger F., Rübe C., Oue T., Vokuhl C., de Krijger R.R., Vujanic G., Sebire N., Coulomb-L'Hermine A., Collini P., Gandola L., Pritchard-Jones K., Graf N., Janssens G.O., van Grotel M.: Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG. PEDIATR BLOOD CANCER (2020); 67 e28039; DOI: 10.1002/pbc.28039PMID: 31625685

Fietkau R., Hecht M., Hofner B., Lubgan D., Iro H., Gefeller O., Rödel C., Hautmann M.G., Kölbl O., Salay A., Rübe C., Melchior P., Breinl P., Krings W., Gripp S., Wollenberg B., Keerl R., Schreck U., Siekmeyer B., Grabenbauer G.G., Balermpas P.: Randomized phase-III-trial of concurrent chemoradiation for locally advanced head and neck cancer comparing dose reduced radiotherapy with paclitaxel/cisplatin to standard radiotherapy with fluorouracil/cisplatin: The PacCis-trial. RADIOTHER ONCOL (2020); 144:209-217; DOI: 10.1016/j.radonc.2020.01.016PMID: 32044419

 

Gkika E., Lenz S., Schimek-Jasch T., Waller C.F., Kremp S., Schaefer-Schuler A., Mix M., Küsters A., Tosch M., Hehr T., Eschmann S.M., Bultel Y.P., Hass P., Fleckenstein J., Thieme A.H., Stockinger M., Dieckmann K., Miederer M., Holl G., Rischke H.C., Adebahr S., König J., Binder H., Grosu A.L., Nestle U.: Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial. CANCERS (2020); 12 3359; , DOI: 10.3390/cancers12113359 PMID: 33202825


Huang K., Madison T., Wehler B., Tiseo M., Wilner K.D., Mo J.: Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe. PHARMACOL RES PERSPE (2020); 8 e00570;DOI: 10.1002/prp2.570 PMID: 32232958

 

Janssens G.O., Mandeville H.C., Timmermann B., Maduro J.H., Alapetite C., Padovani L., Horan G., Lassen-Ramshad Y., Dieckmann K., Ruebe C., Thorp N., Gandola L., Ajithkumar T., Boterberg T.: A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises. RADIOTHER ONCOL (2020); 148:216-222; DOI: 10.1016/j.radonc.2020.04.035PMID: 32342872


Janssens G.O., Melchior P., Mul J., Saunders D., Bolle S., Cameron A.L., Claude L., Gurtner K., van de Ven K.P., van Grotel M., Harrabi S., Lassen-Ramshad Y., Lavan N., Magelssen H., Muracciole X., Boterberg T., Mandeville H., Godzinski J., Graf N., van den Heuvel-Eibrink M.M., Rübe C.: The SIOP-Renal Tumour Study Group consensus statement on flank target volume delineation for highly conformal radiotherapy. LANCET CHILD ADOLESC (2020); 4:846-852; DOI: 10.1016/S2352-4642(20)30183-8PMID: 33068550

Melchior P., Dzierma Y., Rübe C., Graf N., Kager L., Dieckmann K., Kroiss S., Hubertus J., Warmann S., Schenk J.P., Leuschner I., Nemes K., Meier C.M., Vokuhl C., Frühwald M., Furtwängler R.: Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK). INT J RADIAT ONCOL (2020); 108:667-675; DOI: 10.1016/j.ijrobp.2020.04.046PMID: 32407933


Nestle U., Kremp S., Schaefer-Schuler A., Sebastian-Welsch C., Hellwig D., Rube C., Kirsch C.M.: Comparison of Different Methods for Delineation of F-18-FDG PET-Positive Tissue for Target Volume Definition in Radiotherapy of Patients with Non-Small Cell Lung Cancer. J NUCL MED (2020); 61(2):180S-186S; PMID: 16085592


Nestle U., Schimek-Jasch T., Kremp S., Schaefer-Schuler A., Mix M., Küsters A., Tosch M., Hehr T., Eschmann S.M., Bultel Y.P., Hass P., Fleckenstein J., Thieme A., Stockinger M., Dieckmann K., Miederer M., Holl G., Rischke H.C., Gkika E., Adebahr S., König J., Grosu A.L.: Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. LANCET ONCOL (2020); 21:581-592; DOI: 10.1016/S1470-2045(20)30013-9PMID: 32171429


Oertel M., Elsayad K., Engenhart-Cabillic R., Reinartz G., Baues C., Schmidberger H., Vordermark D., Marnitz S., Lukas P., Ruebe C., Engert A., Lenz G., Eich H.T.: Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic: Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. STRAHLENTHER ONKOL (2020); 196:1096-1102; DOI: 10.1007/s00066-020-01705-wPMID: 33125504


Pasqualini C., Furtwängler R., van Tinteren H., Teixeira R.A.P., Acha T., Howell L., Vujanic G., Godzinski J., Melchior P., Smets A.M., Coulomb-L'Hermine A., Brisse H., Pritchard-Jones K., Bergeron C., de Camargo B., van den Heuvel-Eibrink M.M., Graf N., Verschuur A.C.: Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. EUR J CANCER (2020); 128:38-46; DOI: 10.1016/j.ejca.2020.01.001 PMID: 32109849

 

Pater L., Melchior P., Rübe C., Cooper B.T., McAleer M.F., Kalapurakal J.A., Paulino A.C.: Wilms tumor. PEDIATR BLOOD CANCER (2020); 68 e28257; DOI: 10.1002/pbc.28257PMID: 32893998

Reinartz G., Molavi Tabrizi C., Liersch R., Ullerich H., Hering D., Willborn K., Schultze J., Micke O., Ruebe C., Fischbach W., Bentz M., Daum S., Pott C., Tiemann M., Moeller P., Neubauer A., Wilhelm M., Lenz G., Berdel W.E., Willich N., Eich H.T.: Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials. ONCOLOGIST (2020); 25:e816-e832; DOI: 10.1634/theoncologist.2019-0783PMID: 32219909

     

    2019

     

    Sadrollahi A., Nuesken F., Licht N., Rübe Ch., Dzierma Y.: Monte-Carlo simulation of the Siemens Artiste linear accelerator flat 6 MV and flattening-filter-free 7 MV beam line. PLOS ONE (2019); 14:e0210069; DOI 10.1371/journal.pone.0210069 PMID: 30620742

    Eichler M., Hechtner M., Wehler B., Buhl R., Stratmann J., Sebastian M., Schmidberger H., Kortsik C., Nestle U., Wirtz H., Wehler T., Blettner M., Singer S.: Use of psychosocial services by lung cancer survivors in Germany: Results of a German multicenter study (LARIS). STRAHLENTHER ONKOL (2019); 195:1018-1027; DOI: 10.1007/s00066-019-01490-1 PMID: 31292665

    Friedrichs B., Nickelsen M., Ziepert M., Altmann B., Haenel M., Viardot A., Schmidt C., Ruebe C., Loeffler M., Pfreundschuh M., Rosenwald A., Glass B., Lenz G., Schmitz N.: Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. BRIT J HAEMATOL (2019); 184:760-768; DOI: 10.1111/bjh.15710PMID: 30520013

    Gabriel L., Schmidt M., Juhasz-Böss S., Melchior P., von Heesen A., Schmidt G., Kranzhöfer N., Solomayer E.F., Juhasz-Böss I., Breitbach G.P.: Therapy of isolated locoregional recurrent carcinoma of the breast. ARCH GYNECOL OBSTET (2019); 300:365-376; DOI: 10.1007/s00404-019-05220-xPMID: 31222400

    Hoeben B.A., Carrie C., Timmermann B., Mandeville H.C., Gandola L., Dieckmann K., Ramos Albiac M., Magelssen H., Lassen-Ramshad Y., Ondrová B., Ajithkumar T., Alapetite C., Balgobind B.V., Bolle S., Cameron A.L., Davila Fajardo R., Dietzsch S., Dumont Lecomte D., van den Heuvel-Eibrink M.M., Kortmann R.D., Laprie A., Melchior P., Padovani L., Rombi B., Scarzello G., Schwarz R., Seiersen K., Seravalli E., Thorp N., Whitfield G.A., Boterberg T., Janssens G.O.: Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group. LANCET ONCOL (2019); 20:e155-e166; DOI: 10.1016/S1470-2045(19)30034-8 PMID: 30842059

    Niewald M., Melchior P., Dzierma Y., Kremp S., Rübe Ch.: Radiotherapy after tumour prostheses – status, indication, coordination. Orthopäde (2019); 48:605-609; DOI 10.1007/s00132-019-03722-9 PMID: 30919000

     

    Pejović S.M., Pejović M.M., Živanović M.: Small dose effect in RADFET with thick gate oxide. APPL RADIAT ISOTOPES (2019); 152:72-77; DOI: 10.1016/j.apradiso.2019.06.034 PMID: 31280110

    Reinartz G., Pyra R.P., Lenz G., Liersch R., Stüben G., Micke O., Willborn K., Hess C.F., Probst A., Fietkau R., Jany R., Schultze J., Rübe C., Hirt C., Fischbach W., Bentz M., Daum S., Pott C., Tiemann M., Möller P., Neubauer A., Wilhelm M., Willich N., Berdel W.E., Eich H.T.: Favorable radiation field decrease in gastric marginal zone lymphoma: Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL). STRAHLENTHER ONKOL (2019); 195:544-557; DOI: 10.1007/s00066-019-01446-5PMID: 30859254

    2018

     

    Bell K., Dzierma Y., Morlo M., Nüsken F., Licht N., Rübe Ch.: Image guidance in clinical practice – Influence of positioning inaccuracy on the dose distribution for prostate cancer. Physica Medica (2018); 46:81-88; DOI 10.1016/j.ejmp.2018.01.015 PMID: 29519414

     

    Dzierma Y., Mikulla K., Richter P., Bell K., Melchior P., Nuesken F., Rübe Ch.: Imaging dose and secondary cancer risk in image-guided radiotherapy of pediatric patients. Radiat Oncol (2018);13:168; DOI 10.1186/s13014-018-1109-8 PMID: 30185206

     

    Bell K., Licht N., Rübe Ch., Dzierma Y.: Image guidance and positioning accuracy in clinical practice: influence of positioning errors and imaging dose on the real dose distribution for head and neck cancer treatment. Radiat Oncol (2018); 13:190; DOI 10.1186/s13014-018-1141-8 PMID: 30285806

     

    Braun B.J., Huss C., Heimueller S., Klein M., Herath S.C., Ruebe C., Pohlemann T., Niewald M.: Should I Stay or Should I Go? A Prospective, Blinded Study Comparing the Diagnostic Capability of Dynamic and Stationary Pedobarography in Plantar Fasciitis. J FOOT ANKLE SURG (2018); 57:1181-1185; DOI: 10.1053/j.jfas.2018.06.015 PMID: 30368429


    Dávila Fajardo R., Oldenburger E., Rübe C., López-Yurda M., Pritchard-Jones K., Bergeron C., Graf N., van Grotel M., van Tinteren H., Saunders D., van den Heuvel-Eibrink M.M., Janssens G.O., Oldenburger F.: Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry. PEDIATR BLOOD CANCER (2018); 65:e27085; DOI: 10.1002/pbc.27085 PMID: 29693799

    Furtwängler R., Kager L., Melchior P., Rübe C., Ebinger M., Nourkami-Tutdibi N., Niggli F., Warmann S., Hubertus J., Amman G., Leuschner I., Vokuhl C., Graf N., Frühwald M.C.: High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival-The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience. PEDIATR BLOOD CANCER (2018); 65; DOI: 10.1002/pbc.26746PMID: 28843054


    Gooskens S.L., Graf N., Furtwängler R., Spreafico F., Bergeron C., Ramírez-Villar G.L., Godzinski J., Rübe C., Janssens G.O., Vujanic G.M., Leuschner I., Coulomb-L'Hermine A., Smets A.M., de Camargo B., Stoneham S., van Tinteren H., Pritchard-Jones K., van den Heuvel-Eibrink M.M.: Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol. NAT REV UROL (2018); 15:309-319; DOI: 10.1038/nrurol.2018.14 PMID: 29485128


    Stroeder R., Walch-Rückheim B., Fischbach J., Juhasz-Böss I., Rübe C., Solomayer E.F., Smola S.: Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner. ONCOL LETT (2018); 16:3351-3358; DOI: 10.3892/ol.2018.8987 PMID: 30127934

    Vogin G., Fleckenstein J., Servotte J.C., Nickers P., Ebersberger A., Mohammad F., Bragard I., Coucke P., Untereiner M., Peiffert D., Braun M., Greater Region radiation oncology consortium: NHL-ChirEx: An interprofessional cross-border education initiative in the Greater Region with a focus on radiation morbidity and patient safety. RADIOTHER ONCOL (2018); 129:417-420; DOI: 10.1016/j.radonc.2018.06.031PMID: 30001933

       

      2017

       

      Bell K., Heitfeld M., Licht N., Rübe Ch., Dzierma Y.: Influence of daily imaging on plan quality and normal tissue toxicity for prostate cancer radiotherapy. Radiat Oncol (2017); 12:7; DOI 10.1186/s13014-016-0757-9

       

      Furtwängler R., Kager L., Melchior P., Rübe C., Ebinger M., Nourkami-Tutdibi N., Niggli F., Warmann S., Hubertus J., Amman G., Leuschner I., Vokuhl C., Graf N., Frühwald MC.: High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival-The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience. Pediatr Blood Cancer (2017); 65; DOI: 10.1002/pbc.26746PMID: 28843054

       

      Dzierma Y., Minko P., Ziegenhain F., Bell K., Buecker A., Rübe Ch., Jagoda P.: Abdominal imaging dose in radiology and radiotherapy – Phantom point dose measurements, effective dose and secondary cancer risk. Physica Medica (2017); 43:49-56; DOI 10.1016/j.ejmp.2017.10.019

       

      2016

       

      Bell K., Fleckenstein J., Nuesken F., Licht N., Rübe Ch., Dzierma Y.: mARC Treatment of Hypopharynx Carcinoma with Flat and Flattening-Filter-Free Beam Energies – A Planning Study. PLOS ONE (2016); 11; DOI 10.1371/journal.pone.0164616

       

      Dzierma Y., Nuesken F., Licht N., Rübe Ch.: Benchmarking the mARC performance – treatment time and dosimetric linearity. Z Med Phys (2016); 26:339-348; DOI 10.1016/j.zemedi.2016.02.001

       

      Bell K., Dzierma Y., Palm J., Nuesken F., Licht N., Rübe Ch.: mARC prostate treatment planning with Varian Eclipse for flat vs. FFF beams. Physica Medica (2016); 32:474-478; DOI 10.1016/j.ejmp.2016.02.011

       

      Al Kadah B., Niewald M., Papaspyrou G., Dzierma Y., Schneider M., Schick B.: Customized individual applicators for endocavitary brachytherapy in patients with cancer of the nasal cavity, sinonasal region and nasopharynx. Eur Arch Otorhinolaryngol (2016); 273:1543-1547; DOI 10.1007/s00405-015-3636-3

       

      Wemmert S., Lindner Y., Linxweiler J., Wagenpfeil S., Bohle R., Niewald M., Schick B.: First evidence for Sec62 as a new prognostic marker in advanced head and neck squamous cell carcinoma. Oncol Lett (2016); 11:1661-1670; DOI 10.3892/ol.2016.4135


      2015

       

      Dzierma Y., Beyhs M., Palm J., Niewald M., Bell K., Nuesken F., Licht N., Rübe Ch.: Set-up errors and planning margins in planar and CBCT image-guided radiotherapy using three different imaging systems: A clinical study for prostate and head-and-neck cancer. Physica Medica (2015); 31:1055-1059; DOI 10.1007/s00405-015-3636-3

       

      Dzierma Y., Ames E., Nuesken F., Palm J., Licht N., Rübe Ch.: Image quality and dose distributions of three linac-based imaging modalities. Strahlenther Onkol (2015); 191:365-374; DOI 10.1007/s00066-014-0798-7

       

      Dzierma Y., Licht N., Norton I., Nuesken F., Rübe Ch., Fleckenstein J.: VMAT to arclet plan conversion in a treatment planning system. Strahlenther Onkol (2015); 191:961-969; DOI 10.1007/s00066-015-0889-0

       

      Fleckenstein J., Eschler A., Kremp K., Kremp S., Rübe Ch.: Dose distribution and tumor control probability in out-of-field lymph node stations in intensity modulated radiotherapy (IMRT) vs 3D-conformal radiotherapy (3D-CRT) of non-small-cell lung cancer: an in silico analysis. Radiat Oncol (2015); 10:178; DOI 10.1186/s13014-015-0485-6

       

      Holtmann H., Niewald M., Prokein B., Gräber S., Rübe Ch.: Randomized multicenter follow-up trial on the effect of radiotherapy for plantar fasciitis (painful heel spur) depending on dose and fractionation: a study protocol. Radiat Oncol (2015); 10:23; DOI 10.1186/s13014-015-0327-6

       

      Niewald M., Holtman H., Prokein B., Hautmann MG., Rösler H-P., Graeber S., Dzierma Y., Ruebe Ch., Fleckenstein J.: Randomized multicenter follow-up trial on the effect of radiotherapy on painful heel spur (plantar fasciitis) comparing two fractionation schedules with uniform total dose: first results after three months's follow-up. Radiat Oncol (2015); 10:174; DOI 10.1186/s13014-015-0471-z

       

      Ott O.J., Niewald M., Weitmann H.-D., Jacob I., Adamietz I.A., Schäfer U., Keilholz L., Heyd R., Mücke R. and the German Cooperative Group on Radiotherapy of Benign Diseases (GCG-BD): DEGRO guidelines for the radiotherapy of non-malignant disorders. Part II: Painful degenerative skeletal disorders. Strahlenther Onkol (2015); 191:1-6; DOI 10.1007/s00066-014-0757-3

       

      Seegenschmiedt M.H., Micke O., Niewald M., Mücke R., Eich H.T., Kriz J., Heyd R. and the German Cooperative Group on Radiotherapy of Benign Diseases (GCG-BD): DEGRO guidelines for the radiotherapy of non-malignant disorders. Part III: Hyperproliferative disorders. Strahlenther Onkol (2015); 191:541-548; DOI 10.1007/s00066-015-0818-2

       

      2014

       

      Casper M., Petek E., Henn W., Niewald M., Schneider G., Zimmer V., Lammert F., Rädle J.: Multidiscliplinary treatment of desmoid tumours in a female with Gardner´s syndrome and dysmorphic features due to a large interstitial deletion of chemomsome 5q. Q J Med (2014); 107:521-527; DOI 10.1093/qjmed/hcu036

       

      Dzierma Y., Nuesken F.G., Kremp S., Palm J., Licht N.P., Rübe Ch.: Commissioning and first clinical application of mARC treatment. Strahlenther Onkol (2014); 190:1046-1052; DOI 10.1007/s00066-014-0662-9

       

      Dzierma Y., Bell K., Palm J., Nuesken F., Licht N., Rübe Ch.: mARC vs. IMRT radiotherapy of the prostate with flat and flattening-filter-free beam energies, Radiat Oncol (2014); 9:250; DOI 10.1186/s13014-014-0250-2

       

      Dzierma Y., Nuesken F.G., Palm J., Licht N.P., Ruebe Ch.: Planning study and dose measurements of intracranial stereotactic radiation surgery with a flattening filter-free linac. Pract Radiat Oncol (2014); 4:e109-116; DOI 10.1016/j.prro.2013.04.004

       

      Dzierma Y., Nuesken F., Otto W., Alaei P., Licht N., Rübe Ch.: Dosimetry of an in-line kilovoltage imaging system and implementation in treatment planning. Int J Radiat Oncol Biol Phys (2014); 88:913-919; DOI 10.1016/j.ijrobp.2013.12.007

       

      Dzierma Y., Nuesken F.G., Fleckenstein J., Melchior P., Licht N.P., Rübe Ch.: Comparative planning of flattening-filter-free and flat beam IMRT for hypopharynx cancer as a function of beam and segment number. PLOS ONE (2014); 9:e94371; DOI 10.1371/journal.pone.0094371

       

      Held G., Murawski N., Ziepert M., Fleckenstein J., Pöschel V., Zwick C., Bittenbring J., Hänel M., Wilhelm S., Schubert J., Schmitz N., Löffler M., Rübe Ch., Pfreundschuh M.: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol (2014); 32:1112-1118; DOI 10.1200/JCO.2013.51.4505

       

      Murawski N., Held G., Ziepert M., Kempf B., Viardot A., Hänel M., Witzens-Harig M., Mahlberg R., Rübe Ch., Fleckenstein J., Zwick C., Glass B., Schmitz N., Zeynalova S., Pfreundschuh M.: The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood (2014); 124:720-728; DOI 10.1182/blood-2013-10-535021

       

      Niewald M., Mang K., Barbie O., Fleckenstein J., Holtmann H., Spitzer W.J., Rübe Ch.: Dental treatment, dental treatment procedures and radiotherapy as risk factors for infected osteoradionecrosis (IORN) in patients with oral cancer – a comparison of two 10 years’ observation periods. SpringerPlus (2014), 3:263; DOI 10.1186/2193-1801-3-263

       

      2013

       

      Dzierma Y., Nuesken F., Licht N., Ruebe Ch.: A novel implementation of mARC treatment for non-dedicated planning systems using converted IMRT plans. Radiat Oncol (2013); 8:193; DOI 10.1186/1748-717X-8-193

       

      Dzierma Y., Nuesken F.G., Licht N.P., Ruebe Ch.: Dosimetric properties and commissioning of cone-beam CT image beam line with a carbon target. Strahlenther Onkol (2013); 189:566-572; DOI 10.1007/s00066-013-0330-5

       

      Dzierma Y., Nuesken F.G., Fleckenstein J., Kremp S., Licht N.P., Ruebe Ch.: Visualisation of respiratory tumour motion and co-moving isodose lines in the context of respiratory gating, IMRT and flattening-filter-free beams. PLOS ONE (2013); 8:e53799; DOI 10.1371/journal.pone.0053799

       

      Fietkau R., Lewitzki V., Kuhnt T., Baumann M., Hess C-F., Berger B., Wiegel T., Rödel C.M., Niewald M., Hermann R.M., Lubgan D.: A disease-specific enteral nutrition formula high in protein and EPA improves parameters of nutritional status und functional performance in patients with head and neck- and oesophageal cancer undergoing concurrent chemoradiotherapy – a randomised controlled multicenter trial. Cancer (2013); 119:3343-3353; DOI 10.1002/cncr.28197

       

      Held G., Zeynalova S., Murawski N., Ziepert M., Kempf B., Viardot A., Dreyling M., Hallek M., Witzens-Harig M., Fleckenstein J., Rübe Ch., Zwick C., Glass B., Schmitz N., Pfreundschuh M.: Impact of rituximab and radiotherapy on outcome of patients with  aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol (2013); 31:4115-4122; DOI 10.1200/JCO.2012.48.0467

       

      Niewald M., Weitmann H.-D., Rübe Ch.: Radiotherapie der Schulter. Tägliche Praxis (2013), 54:97-103 (Nachdruck von Nr. 30).

       

      Niewald M., Fleckensten J., Mang K., Holtmann H., Spitzer W.J., Rübe Ch.: Dental status, dental rehabilitation procedures, demographic and oncological data as potential risk factors for infected osteoradionecrosis of the lower jaw after radiotherapy for oral neoplasms: a retrospective evaluation. Radiat Oncol (2013); 8:227; DOI 10.1186/1748-717X-8-227

       

      Niewald M.: S2E-Leitlinie „Gutartige Erkrankungen“: Kapitel „Induratio penis plastica“ und „Schmerzhafter Fersensporn“

       

      Schaefer A., Kim Y.J., Kremp S., Mai S., Fleckenstein J., Bohnenberger H., Schäfers H.J., Kuhnigk J.M., Bohle R.M., Rübe Ch., Kirsch C.M., Grgic A.: PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings. Eur J Nucl Med Mol Imaging (2013); 40:1233-1244; DOI 10.1007/s00259-013-2407-x

       

      Weitmann H.-D., Niewald M.: Nicht nur bei Arthrosen erfolgversprechend - Niedrig dosierte Strahlentherapie. MMW-Fortschr Med (2013); 155:43-47; DOI 10.1007/s15006-013-0042-x

       

      Horton P., Lilicrap S., Lamm I.-L., Lehmann W.: Introduction to suspension Levels: Radiotherapy. Radiation Protection Dosim (2013); 153:174-178; DOI 10.1093/rpd/ncs290

       

      Lamm I.-L., Horton P., Lehmann W., Lilicrap S.: Practical Applicabillity of suspension criteria scenarios: Radiotherapy. Radiation Protection Dosim (2013); 153:179-184; DOI 10.1093/rpd/ncs292


      2012

       

      Dzierma Y., Licht N., Nuesken F., Ruebe Ch.: Beam properties and stability of a flattening-filter free 7 MV beam-an overview. Med Phys (2012); 39:2595-2602; DOI 10.1118/1.3703835

       

      Koeck J., Abo-Madyan Y., Eich H.T., Stieler F., Fleckenstein J., Kriz J., Mueller R.P., Wenz F., Lohr F.: Clinical relevance of different dose calculation strategies for mediastinal IMRT in Hodgkin's disease. Strahlenther Onkol (2012); 188:653-659; DOI 10.1007/s00066-012-0144-x

       

      Niewald M., Seegenschmiedt M.H., Micke O., Gräber St., Mücke R., Schäfer V., Scheid C., Fleckenstein J., Licht N., Rübe Ch.: Randomized, multicenter trial on the effect of radiation therapy on plantar fasciitis (painful heel spur) comparing a standard dose with a very low dose – mature results after 12 months’ follow-up. Int J Radiat Oncol Biol Phys (2012); 84:e455-e462; DOI 10.1016/j.ijrobp.2012.06.022

       

      Niewald M., Weitmann H.-D., Rübe Ch.: Radiotherapie der Schulter. Internistische Praxis (2012); 52:789-795

       

      Niewald M.: Wieder Joggen – Fersensyndrom in: Micke O., Rödel F., Seegenschmiedt M.H. (Hrsg,): Benign reloaded – 1. OWL-Symposium „Strahlentherapie Nicht-maligner Erkrankungen“ (2012). Diplodocus, Bielefeld, 2012, pp. 44-53

       

      Schaefer A., Nestle U., Kremp S., Hellwig D., Grgc A., Buchholz H.G., Mischke W., Gromoll C., Dennert P., Plotkin M., Senftleben S., Thorwarth D., Trosch M., Wahl A., Wengenmair H., Rübe Ch., Kirsch C.M.: Multi-centre calibration of an adaptive thresholding method for PET-based delineation of tumour volumes in radiotherapy planning of lung cancer. Nukmed (2012); 51:101-110; DOI 10.3413/Nukmed-0452-11-12

       

       

      White Paper:

       

      Dzierma Y., Nuesken F., Licht N., Ruebe Ch., 2013, Flattening-filter-free beam-line MultipleX (7 MV), Siemens publication

       

      Dzierma Y., Nuesken F., Licht N., Kremp S., Ruebe Ch., 2013, Modulated arc (mARC): principle and clinical implementation, Siemens publication